Assembly Biosciences
Zhixin Z. has a diverse work experience in the pharmaceutical industry. They started at Boehringer Ingelheim as an intern in 2009. In 2010, they moved on to Novartis where they worked as a Senior Scientist, focusing on formulation development for TABRECTA® (capmatinib) and solid characterization for APIs and excipients. In 2012, Zhixin joined Purdue Pharma L.P. as a Senior Research Scientist and later became a Lead Scientist, working on various research projects. In 2016, they transitioned to Bristol Myers Squibb as a Senior Research Investigator I and eventually became a Senior Research Investigator II, specializing in formulation and preformulation development and drug stability risk assessment. Finally, in 2019, Zhixin joined Assembly Biosciences, Inc. as the Director of Drug Product Development and Manufacture, and later became the Senior Director and Head of Drug Product Development.
Zhixin Z. has a Bachelor of Science degree in Chemistry from Lanzhou University. After completing their undergraduate studies, they pursued a Master of Science degree in Analytical Chemistry from the same university. Zhixin Z. then furthered their education and obtained a Ph.D. in Pharmaceutics from the University of Iowa.
Assembly Biosciences
9 followers
Assembly Biosciences (NASDAQ: ASMB) is a clinical-stage biotechnology company committed to bringing finite and curative therapies to the 270 million people living with hepatitis B virus (HBV) worldwide. A pioneer in the development of a new class of potent, oral core inhibitor drug candidates, Assembly Bio’s approach aims to break the complex viral replication cycle of HBV to free patients from a lifetime of therapy. Assembly Bio’s strategy toward cure includes a leading portfolio of more potent, next-generation core inhibitors, proof-of-concept combination studies and a research program focused on the discovery of novel HBV targets.